ClinicalTrials.gov record
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

ClinicalTrials.gov ID: NCT07100106

Public ClinicalTrials.gov record NCT07100106. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 8:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase Ib/II Multicenter, Open-Label, Randomized Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-4198 Alone and in Combination With Giredestrant in Comparison With Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive, HER2-Negative Breast Cancer Who Have Previously Progressed During or After a CDK4/6 Inhibitor

Study identification

NCT ID
NCT07100106
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Genentech, Inc.
Industry
Enrollment
285 participants

Conditions and interventions

Conditions

Interventions

  • Abemaciclib Drug
  • GDC-4198 Drug
  • Giredestrant Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 6, 2025
Primary completion
Aug 30, 2028
Completion
Aug 30, 2028
Last update posted
Apr 20, 2026

2025 – 2028

United States locations

U.S. sites
14
U.S. states
11
U.S. cities
14
Facility City State ZIP Site status
City of Hope Duarte California 91010 Recruiting
City of Hope - Orange County Lennar Foundation Cancer Center Irvine California 92618 Recruiting
UCSF Helen Diller Family CCC San Francisco California 94158 Recruiting
Moffitt Cancer Center Tampa Florida 33612 Recruiting
Winship Cancer Institute of Emory University Atlanta Georgia 30322-1013 Recruiting
City of Hope® Cancer Center Chicago Zion Illinois 60099 Recruiting
Barbara Ann Karmanos Cancer Institute Detroit Maine 48201-2013 Recruiting
Washington University Siteman Cancer Center St Louis Missouri 63110-1010 Recruiting
Rutgers Cancer Institute of New Jersey New Brunswick New Jersey 08901-1914 Recruiting
New York Cancer & Blood Specialists East Patchogue New York 11772 Recruiting
University of Pennsylvania - Abramson Cancer Center Philadelphia Pennsylvania 19104 Recruiting
UPMC - Hillman Cancer Center Pittsburgh Pennsylvania 15213-3108 Recruiting
Vanderbilt Breast Center at One Hundred Oaks Nashville Tennessee 37204-3609 Recruiting
Texas Oncology (Worth) - USOR Dallas Texas 75246-2003 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07100106, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 20, 2026 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07100106 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →